Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”
This paper discusses the potential of an international agreement to ensure equitable vaccine distribution, addressing the failures witnessed during the COVID-19 pandemic. COVAX was unable to prevent vaccine monopolization and unequal distribution, which led to significant disparities in vaccination rates and avoidable deaths. Any future agreement on equitable vaccine distribution must address ethical and practical issues to ensure global health equity and access. The proposed agreement should recognize healthcare as a human right and consider vaccines beyond mere commodities, emphasizing the social responsibility of pharmaceutical companies to prioritize affordability, availability, and accessibility, particularly for low-income countries (LICs). Voluntary licensing agreements are suggested as a means to enhance access to essential medicines. The paper also outlines the necessity of international cooperation, with robust compliance mechanisms, to effectively enforce such an agreement and mitigate future health crises.
Dyer O. COVID-19: countries are learning what others paid for vaccines. BMJ. 2021;372:n281. doi:1136/bmj.n281
Bollyky TJ, Bown CP. The tragedy of vaccine nationalism: only cooperation can end the pandemic. Foreign Aff. 2020;99(5):96-108.
Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic. Nat Med. 2022;28(11):2416-2423. doi:1038/s41591-022-02064-y
Borges LC, Zeferino de Menezes H, Crosbie E. More pain, more gain! The delivery of COVID-19 vaccines and the pharmaceutical industry's role in widening the access gap. Int J Health Policy Manag. 2022;11(12):3101-3113. doi:34172/ijhpm.2022.6942
Emanuel EJ, Buchanan A, Chan SY, et al. What are the obligations of pharmaceutical companies in a global health emergency? Lancet. 2021;398(10304):1015-1020. doi:1016/s0140-6736(21)01378-7
Gore C, Morin S, Røttingen JA, Kieny MP. Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story. BMJ Glob Health. 2023;8(9):e012964. doi:1136/bmjgh-2023-012964
Emanuel EJ, Persad G, Kern A, et al. An ethical framework for global vaccine allocation. Science. 2020;369(6509):1309-1312. doi:1126/science.abe2803
Ortiz-Millán G. How populism affects bioethics. Camb Q Healthc Ethics. 2024:1-15. doi:1017/s0963180124000161
Scholz M, Smith NC, Riegler M, Burton A. Public health and political corporate social responsibility: pharmaceutical company engagement in COVAX. Bus Soc. 2024;63(4):813-850. doi:1177/00076503231158600
Kavanagh MM, Wenham C, Massard da Fonseca E, et al. Increasing compliance with international pandemic law: international relations and new global health agreements. Lancet. 2023;402(10407):1097-1106. doi:1016/s0140-6736(23)01527-1
Singer PA. Replenishment of the Global Fund: global solidarity needed. Lancet. 2016;388(10050):1139-1141. doi:1016/s0140-6736(16)31601-4
Kaddar M, Furrer E. Are current debt relief initiatives an option for scaling up health financing in beneficiary countries? Bull World Health Organ. 2008;86(11):877-883. doi:2471/blt.08.053686
Fu X, Buckley PJ, Sanchez-Ancochea D, Hassan I. The world has a unique opportunity: accelerating technology transfer and vaccine production through partnerships. J Int Bus Policy. 2022;5(3):406-415. doi:1057/s42214-021-00124-7
Hoffman SJ, Baral P, Rogers Van Katwyk S, et al. International treaties have mostly failed to produce their intended effects. Proc Natl Acad Sci U S A. 2022;119(32):e2122854119. doi:1073/pnas.2122854119
Ortiz-Millán, G. (2024). Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”. International Journal of Health Policy and Management, 13(1), 1-4. doi: 10.34172/ijhpm.2024.8516
MLA
Gustavo Ortiz-Millán. "Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”", International Journal of Health Policy and Management, 13, 1, 2024, 1-4. doi: 10.34172/ijhpm.2024.8516
HARVARD
Ortiz-Millán, G. (2024). 'Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”', International Journal of Health Policy and Management, 13(1), pp. 1-4. doi: 10.34172/ijhpm.2024.8516
VANCOUVER
Ortiz-Millán, G. Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access; Comment on “More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry’s Role in Widening the Access Gap”. International Journal of Health Policy and Management, 2024; 13(1): 1-4. doi: 10.34172/ijhpm.2024.8516